Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Primary thrombocythemia: a current perspective

T I Mughal1

  • 1Department of Medicine, King Fahad National Guard Hospital, Riyadh, Saudi Arabia.

Stem Cells (Dayton, Ohio)
|July 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Novel PDGFRB fusions in childhood B- and T-acute lymphoblastic leukemia.

Leukemia·2017
Same author

Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker.

Blood cancer journal·2017
Same author

Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both.

Leukemia·2016
Same author

Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era?

Bone marrow transplantation·2015
Same author

Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib.

Current medicinal chemistry·2012
Same journal

Brent A. Reynolds, pioneer of adult neural stem cell biology.

Stem cells (Dayton, Ohio)·2026
Same journal

CircVapa promotes the abnormal differentiation of small intestinal epithelial stem cells in diabetic state.

Stem cells (Dayton, Ohio)·2026
Same journal

Transforming Growth Factor beta-2 (TGFβ2) Drives Trabecular Meshwork Progenitor Cell Differentiation Through SMAD2/3 Signalling.

Stem cells (Dayton, Ohio)·2026
Same journal

Circular RNA circEGFR overexpression attenuates chemosensitivity and enhances cancer stemness via targeting IGF2BP2/SOX2 in breast cancer cells.

Stem cells (Dayton, Ohio)·2026
Same journal

Regeneration of the mammalian brain: a relic of evolution?

Stem cells (Dayton, Ohio)·2026
Same journal

Mitochondrial transfer technologies with molecular insights into clinical applications.

Stem cells (Dayton, Ohio)·2026
See all related articles

Primary thrombocythemia management is complex due to unclear links between platelet issues and bleeding. New treatments like anagrelide show promise for both symptomatic and asymptomatic patients.

Area of Science:

  • Hematology
  • Oncology

Background:

  • Primary thrombocythemia involves thrombocytosis, abnormal platelet aggregation, and altered hemostasis, but these relationships are not well understood.
  • The management of asymptomatic primary thrombocythemia remains controversial, necessitating individualized treatment approaches.

Purpose of the Study:

  • To review current understanding of primary thrombocythemia pathogenesis.
  • To discuss management guidelines, including conventional and novel therapies.

Main Methods:

  • Review of existing literature on primary thrombocythemia.
  • Discussion of therapeutic options and their mechanisms of action.

Main Results:

  • Conventional therapy (e.g., hydroxyurea) aims to reduce platelet counts by suppressing megakaryocyte activity.

Related Experiment Videos

  • Recombinant interferon alpha offers an alternative for lowering platelet counts.
  • Anagrelide shows promising results in managing both symptomatic and asymptomatic patients.

    • Conclusions:

    • Understanding the pathogenesis of primary thrombocythemia is crucial for effective management.
    • Individualized treatment strategies are essential, especially for asymptomatic patients.
    • Anagrelide represents a promising therapeutic option for primary thrombocythemia.